Mar 16, 2022 / 03:45PM GMT
Carter Lewis Gould - Barclays Bank PLC, Research Division - Senior Analyst
Okay. Good morning, and welcome to Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I'm pleased to welcome Cytokinetics to the stage here. We are -- Cytokinetics is one of our favorite names here looking into 2022. Every year, market serves up these high-quality assets with blockbuster potential, and we think aficamten is absolutely one of those.
And so we're presenting the company, today with CEO, Robert Blum. And we're going to take a little bit of a different spin. We're not going to leave with aficamten. We're going to kind of do this in sort of reverse order. And I want to talk first around relosemtib, as an asset, it doesn't get much attention, and you do have a readout coming up.
Questions and Answers:
Carter Lewis Gould - Barclays Bank PLC, Research Division - Senior AnalystSo I guess when we think about the COURAGE ALS study, can you maybe just set the stage for that study based on some of the earlier work
Trustpilot
